Scholarlink

Objectives <p>To examine consumer perspectives regarding medicinal cannabis treatment provided to patients attending generalist health settings (GHS) compared to those attending medicinal cannabis clinics (MCC).</p> Methods <p>An anonymous online survey, with convenience sampling of adults self-reporting prescribed medicinal cannabis in the preceding 12 months. Outcomes included participant characteristics, indications and patterns of cannabis use, consumer satisfaction.</p> Results <p>Most participants (1899/2394, 79.3%) accessed treatment from MCC. Compared to generalist settings, MCC participants were younger (3.5 years, 95%CI: -4.7, -2.2), less likely to be prescribed oral products (OR = 0.4, 0.4–0.5), and had higher rates of employment (OR = 2.1, 1.8–2.5) and cannabis use disorder (OR = 1.5, 1.2–1.8). MCC participants were less likely to seek treatment for chronic pain (OR = 0.7, 0.6–0.8), but more likely for mental health conditions (OR = 1.6, 1.3-2.0). MCC participants had lower satisfaction levels regarding consultation duration (OR = 0.8, 0.7–0.9), information about potential harms and benefits (OR = 0.7, 0.6–0.9), use of other treatment approaches (OR = 0.5, 0.4–0.6) and treatment costs (OR = 0.6, 0.5–0.7).</p> Conclusion <p>We identified differences in the profile of patients, type of treatment provided between service settings, and there were higher levels of satisfaction amongst consumers accessing treatment in GHS settings. Further research is required to examine other dimensions of quality and appropriateness of care provided in MCC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Consumer perspectives of accessing medicinal cannabis treatment from cannabis clinics versus generalist health settings in Australia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月27日

查看全文
  • Nicholas Lintzeris,
  • Jonathon C Arnold,
  • Iain S McGregor,
  • Llewellyn Mills

摘要

Objectives

To examine consumer perspectives regarding medicinal cannabis treatment provided to patients attending generalist health settings (GHS) compared to those attending medicinal cannabis clinics (MCC).

Methods

An anonymous online survey, with convenience sampling of adults self-reporting prescribed medicinal cannabis in the preceding 12 months. Outcomes included participant characteristics, indications and patterns of cannabis use, consumer satisfaction.

Results

Most participants (1899/2394, 79.3%) accessed treatment from MCC. Compared to generalist settings, MCC participants were younger (3.5 years, 95%CI: -4.7, -2.2), less likely to be prescribed oral products (OR = 0.4, 0.4–0.5), and had higher rates of employment (OR = 2.1, 1.8–2.5) and cannabis use disorder (OR = 1.5, 1.2–1.8). MCC participants were less likely to seek treatment for chronic pain (OR = 0.7, 0.6–0.8), but more likely for mental health conditions (OR = 1.6, 1.3-2.0). MCC participants had lower satisfaction levels regarding consultation duration (OR = 0.8, 0.7–0.9), information about potential harms and benefits (OR = 0.7, 0.6–0.9), use of other treatment approaches (OR = 0.5, 0.4–0.6) and treatment costs (OR = 0.6, 0.5–0.7).

Conclusion

We identified differences in the profile of patients, type of treatment provided between service settings, and there were higher levels of satisfaction amongst consumers accessing treatment in GHS settings. Further research is required to examine other dimensions of quality and appropriateness of care provided in MCC.